JP6803084B2 - 網膜光線療法のためのシステムとプロセス - Google Patents
網膜光線療法のためのシステムとプロセス Download PDFInfo
- Publication number
- JP6803084B2 JP6803084B2 JP2018503675A JP2018503675A JP6803084B2 JP 6803084 B2 JP6803084 B2 JP 6803084B2 JP 2018503675 A JP2018503675 A JP 2018503675A JP 2018503675 A JP2018503675 A JP 2018503675A JP 6803084 B2 JP6803084 B2 JP 6803084B2
- Authority
- JP
- Japan
- Prior art keywords
- laser
- retinal
- treatment
- laser beam
- retina
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002207 retinal effect Effects 0.000 title claims description 116
- 238000001126 phototherapy Methods 0.000 title claims description 37
- 238000000034 method Methods 0.000 title description 71
- 230000008569 process Effects 0.000 title description 9
- 210000001525 retina Anatomy 0.000 claims description 120
- 230000003287 optical effect Effects 0.000 claims description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 230000007246 mechanism Effects 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 17
- 230000000638 stimulation Effects 0.000 claims description 8
- 230000000007 visual effect Effects 0.000 claims description 7
- 239000003550 marker Substances 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 182
- 230000000649 photocoagulation Effects 0.000 description 73
- 210000001519 tissue Anatomy 0.000 description 52
- 230000001225 therapeutic effect Effects 0.000 description 33
- 210000001508 eye Anatomy 0.000 description 32
- 230000006378 damage Effects 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 27
- 206010012689 Diabetic retinopathy Diseases 0.000 description 24
- 208000017442 Retinal disease Diseases 0.000 description 24
- 230000000694 effects Effects 0.000 description 19
- 230000000451 tissue damage Effects 0.000 description 19
- 231100000827 tissue damage Toxicity 0.000 description 19
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 18
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 18
- 230000003902 lesion Effects 0.000 description 18
- 206010057430 Retinal injury Diseases 0.000 description 17
- 210000000695 crystalline len Anatomy 0.000 description 17
- 238000002647 laser therapy Methods 0.000 description 17
- 201000004569 Blindness Diseases 0.000 description 15
- 230000004393 visual impairment Effects 0.000 description 15
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 14
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 14
- 206010025421 Macule Diseases 0.000 description 14
- 201000011190 diabetic macular edema Diseases 0.000 description 14
- 206010064930 age-related macular degeneration Diseases 0.000 description 11
- 208000002780 macular degeneration Diseases 0.000 description 11
- 230000000254 damaging effect Effects 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 239000000835 fiber Substances 0.000 description 9
- 208000018769 loss of vision Diseases 0.000 description 9
- 231100000864 loss of vision Toxicity 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 230000017525 heat dissipation Effects 0.000 description 8
- 229910052786 argon Inorganic materials 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 230000004438 eyesight Effects 0.000 description 7
- 231100000241 scar Toxicity 0.000 description 7
- 230000004304 visual acuity Effects 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 231100000518 lethal Toxicity 0.000 description 6
- 230000001665 lethal effect Effects 0.000 description 6
- 238000012014 optical coherence tomography Methods 0.000 description 6
- 208000014139 Retinal vascular disease Diseases 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 238000002583 angiography Methods 0.000 description 5
- 230000007012 clinical effect Effects 0.000 description 5
- 230000001066 destructive effect Effects 0.000 description 5
- 230000009931 harmful effect Effects 0.000 description 5
- 239000013307 optical fiber Substances 0.000 description 5
- 230000000750 progressive effect Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 238000005338 heat storage Methods 0.000 description 4
- 230000019612 pigmentation Effects 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 230000004243 retinal function Effects 0.000 description 4
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 208000002177 Cataract Diseases 0.000 description 3
- 208000010412 Glaucoma Diseases 0.000 description 3
- 208000001344 Macular Edema Diseases 0.000 description 3
- 206010025415 Macular oedema Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000005779 cell damage Effects 0.000 description 3
- 208000037887 cell injury Diseases 0.000 description 3
- 210000003161 choroid Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000000873 fovea centralis Anatomy 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 201000010230 macular retinal edema Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000001328 optic nerve Anatomy 0.000 description 3
- 238000013021 overheating Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000011268 retreatment Methods 0.000 description 3
- 230000037390 scarring Effects 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 201000007737 Retinal degeneration Diseases 0.000 description 2
- 206010038848 Retinal detachment Diseases 0.000 description 2
- 206010038895 Retinal scar Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 208000034698 Vitreous haemorrhage Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 210000001747 pupil Anatomy 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000004258 retinal degeneration Effects 0.000 description 2
- 239000000790 retinal pigment Substances 0.000 description 2
- 230000004268 retinal thickening Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000011272 standard treatment Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 238000003325 tomography Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 208000032484 Accidental exposure to product Diseases 0.000 description 1
- 208000003569 Central serous chorioretinopathy Diseases 0.000 description 1
- 208000033379 Chorioretinopathy Diseases 0.000 description 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000031942 Late Onset disease Diseases 0.000 description 1
- 208000031471 Macular fibrosis Diseases 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- 208000007135 Retinal Neovascularization Diseases 0.000 description 1
- 206010064145 Retinal aneurysm Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 208000036038 Subretinal fibrosis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 231100000818 accidental exposure Toxicity 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 230000004456 color vision Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000013479 data entry Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 208000011325 dry age related macular degeneration Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000004424 eye movement Effects 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 1
- 229960004657 indocyanine green Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 208000010746 intraretinal hemorrhage Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052743 krypton Inorganic materials 0.000 description 1
- DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000000886 photobiology Effects 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 210000000608 photoreceptor cell Anatomy 0.000 description 1
- 201000009015 preretinal fibrosis Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 230000004283 retinal dysfunction Effects 0.000 description 1
- 230000004253 retinal exposure Effects 0.000 description 1
- 230000004262 retinal health Effects 0.000 description 1
- 230000004286 retinal pathology Effects 0.000 description 1
- 230000004517 retinal physiology Effects 0.000 description 1
- 208000004644 retinal vein occlusion Diseases 0.000 description 1
- 210000001210 retinal vessel Anatomy 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 201000003772 severe nonproliferative diabetic retinopathy Diseases 0.000 description 1
- 210000002301 subretinal fluid Anatomy 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000003685 thermal hair damage Effects 0.000 description 1
- 210000001585 trabecular meshwork Anatomy 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
- A61F9/00821—Methods or devices for eye surgery using laser for coagulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
- A61F2009/00861—Methods or devices for eye surgery using laser adapted for treatment at a particular location
- A61F2009/00863—Retina
Landscapes
- Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Laser Surgery Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Radiation-Therapy Devices (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
Claims (9)
- 網膜光線療法あるいは光刺激を行うためのシステムであって、
マイクロパルスレーザー光線を生成するレーザーコンソールと、
レーザー光線を光学的に形成するために、レーザー光線が通過する光学レンズまたはマスクと、
網膜光線療法あるいは光刺激を行うための所望の部位の領域へレーザー光線を投影する同軸の広視野非接触型のデジタル光視認カメラと、
機構であって、網膜光線療法あるいは光刺激を行うための所望の部位の少なくとも1つの他の領域に、マイクロパルス間隔中のレーザー光線を制御可能に移動させ、その後、あらかじめ処置された領域にレーザー光線を再適用するため1ミリ秒から3ミリ秒以内に、あらかじめ処置された領域にレーザー光線を戻す、機構とを含む、
システム。 - レーザー光線は、網膜光線療法あるいは光刺激を行うための所望の部位の完全な適用範囲を達成するために、制御可能に移動させられる、請求項1に記載のシステム。
- レーザー光線は、網膜光線療法あるいは光刺激を行うための所望の部位上の疾患マーカーに選択的に適用される、請求項1または2に記載のシステム。
- レーザー光線は、網膜光線療法あるいは光刺激を行うための所望の部位の中心の少なくとも一部に投影される、請求項1−3のいずれかに記載のシステム。
- 光学レンズまたはマスクは、レーザー光線から複数のスポットを生成するために、回折光学素子を含み、ここで、複数のスポットは、同軸の広視野の非接触型デジタル光視認カメラから、網膜光線療法あるいは光刺激を行うための所望の部位の少なくとも一部まで投影される、請求項1−4のいずれかに記載のシステム。
- 網膜診断モダリティからの結果画像に平行に、あるいは、前記結果画像の上に重ねて表示される、網膜光線療法あるいは光刺激を行うための所望の部位の眼底画像をさらに含む、請求項1−5のいずれかに記載のシステム。
- レーザーコンソールは、網膜の所望の部位の領域へ同時に適用され且つ移動される複数のマイクロパルス光線を生成する、請求項1−5のいずれかに記載のシステム。
- マイクロパルスレーザー光線は532nm以上、好ましくは750nm−1300nmの間のレーザー光波長を備え、ここで、レーザー光線はマイクロパルスであり、10%未満、好ましくは5%未満のデューティサイクルを有し、適用されるパルスは1ミリ秒未満の持続時間、好ましくは50マイクロ秒から100マイクロ秒の間の持続時間である、請求項1−5ないし7のいずれかに記載のシステム。
- 少なくとも複数の光線は異なる波長を有する、請求項7−8のいずれかに記載のシステム。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/921,890 | 2015-10-23 | ||
US14/921,890 US9381116B2 (en) | 2012-05-25 | 2015-10-23 | Subthreshold micropulse laser prophylactic treatment for chronic progressive retinal diseases |
US15/148,842 | 2016-05-06 | ||
US15/148,842 US10363171B2 (en) | 2012-05-25 | 2016-05-06 | System and process for retina phototherapy |
PCT/US2016/042200 WO2017069819A1 (en) | 2015-10-23 | 2016-07-14 | System and process for retina phototherapy |
Publications (4)
Publication Number | Publication Date |
---|---|
JP2018531051A JP2018531051A (ja) | 2018-10-25 |
JP2018531051A6 JP2018531051A6 (ja) | 2018-12-13 |
JP2018531051A5 JP2018531051A5 (ja) | 2019-08-22 |
JP6803084B2 true JP6803084B2 (ja) | 2020-12-23 |
Family
ID=58558255
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018503675A Active JP6803084B2 (ja) | 2015-10-23 | 2016-07-14 | 網膜光線療法のためのシステムとプロセス |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP3364925B1 (ja) |
JP (1) | JP6803084B2 (ja) |
CN (1) | CN108024870B (ja) |
AU (2) | AU2016342091B2 (ja) |
BR (1) | BR112018005267A2 (ja) |
CA (1) | CA2994110C (ja) |
ES (1) | ES2905773T3 (ja) |
HK (1) | HK1252431A1 (ja) |
SG (1) | SG11201800734QA (ja) |
WO (1) | WO2017069819A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG185517A1 (en) | 2010-05-10 | 2012-12-28 | Univ Ramot | System for treating glaucoma by directing electromagnetic energy to the limbal area of an eye |
US11771596B2 (en) | 2010-05-10 | 2023-10-03 | Ramot At Tel-Aviv University Ltd. | System and method for treating an eye |
CN110582238A (zh) * | 2017-05-01 | 2019-12-17 | 奥哈伊视网膜技术有限责任公司 | 用于治疗近视的系统及方法 |
IL279749B2 (en) | 2018-07-02 | 2024-04-01 | Belkin Vision Ltd | Direct selective laser trabeculoplasty |
US10675481B1 (en) * | 2019-08-20 | 2020-06-09 | Nikolai Tankovich | Laser system for multiple beam tissue therapy |
CN113995526B (zh) * | 2021-11-30 | 2024-02-23 | 南京朔视科技开发有限公司 | 一种用于确定视力矫正外科手术治疗区域的系统 |
CN116236701A (zh) * | 2023-01-12 | 2023-06-09 | 北京鹰瞳科技发展股份有限公司 | 一种用于近视防控的光路系统 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4764930A (en) * | 1988-01-27 | 1988-08-16 | Intelligent Surgical Lasers | Multiwavelength laser source |
US5951596A (en) * | 1991-07-01 | 1999-09-14 | Laser Biotherapy Inc | Biological tissue stimulation by optical energy |
US5921981A (en) * | 1995-11-09 | 1999-07-13 | Alcon Laboratories, Inc. | Multi-spot laser surgery |
US6789900B2 (en) * | 1996-11-22 | 2004-09-14 | Jozef F. Van De Velde | Scanning laser ophthalmoscope optimized for selective retinal microphotocoagulation |
US5892569A (en) * | 1996-11-22 | 1999-04-06 | Jozef F. Van de Velde | Scanning laser ophthalmoscope optimized for retinal microphotocoagulation |
US6186628B1 (en) * | 1999-05-23 | 2001-02-13 | Jozek F. Van de Velde | Scanning laser ophthalmoscope for selective therapeutic laser |
US6494878B1 (en) * | 2000-05-12 | 2002-12-17 | Ceramoptec Industries, Inc. | System and method for accurate optical treatment of an eye's fundus |
US7081128B2 (en) * | 2002-03-04 | 2006-07-25 | Hart Barry M | Phototherapy device and method of use |
US20040087886A1 (en) * | 2002-10-30 | 2004-05-06 | Scimed Life Systems, Inc. | Linearly expandable ureteral stent |
RU2460503C2 (ru) * | 2006-11-10 | 2012-09-10 | Ларс Михаэль ЛАРСЕН | Способ и устройство для неразрушающей или минимально разрушающей световой обработки глаза |
DK2170232T3 (en) | 2007-05-30 | 2017-09-25 | Ellex R&D Pty Ltd | Laser for retinal rejuvenation |
DE102010022760A1 (de) * | 2010-06-04 | 2011-12-08 | Carl Zeiss Meditec Ag | Ophthalmologisches Gerät zur Photokoagulation oder Phototherapie und Betriebsverfahren für ein solches |
US10238541B2 (en) * | 2011-10-19 | 2019-03-26 | Iridex Corporation | Short duration pulse grid pattern laser treatment and methods |
EP2768378B1 (en) * | 2011-10-19 | 2021-12-22 | Iridex Corporation | Grid pattern laser treatments |
US9849034B2 (en) * | 2011-11-07 | 2017-12-26 | Alcon Research, Ltd. | Retinal laser surgery |
US10219947B2 (en) * | 2012-05-25 | 2019-03-05 | Ojai Retinal Technology, Llc | System and process for retina phototherapy |
US9381115B2 (en) * | 2012-05-25 | 2016-07-05 | Ojai Retinal Technology, Llc | System and process for retina phototherapy |
JP6439271B2 (ja) * | 2013-04-30 | 2018-12-19 | 株式会社ニデック | レーザ治療装置 |
CN103949771B (zh) * | 2014-02-13 | 2015-06-24 | 同济大学 | 一种基于特征人工节瘤缺陷的激光预处理技术 |
-
2016
- 2016-07-14 EP EP16857925.8A patent/EP3364925B1/en active Active
- 2016-07-14 WO PCT/US2016/042200 patent/WO2017069819A1/en active Application Filing
- 2016-07-14 AU AU2016342091A patent/AU2016342091B2/en active Active
- 2016-07-14 ES ES16857925T patent/ES2905773T3/es active Active
- 2016-07-14 CA CA2994110A patent/CA2994110C/en active Active
- 2016-07-14 BR BR112018005267A patent/BR112018005267A2/pt not_active Application Discontinuation
- 2016-07-14 SG SG11201800734QA patent/SG11201800734QA/en unknown
- 2016-07-14 CN CN201680054425.8A patent/CN108024870B/zh active Active
- 2016-07-14 JP JP2018503675A patent/JP6803084B2/ja active Active
-
2018
- 2018-09-12 HK HK18111732.0A patent/HK1252431A1/zh unknown
-
2021
- 2021-08-11 AU AU2021215167A patent/AU2021215167B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN108024870A (zh) | 2018-05-11 |
BR112018005267A2 (pt) | 2018-10-09 |
ES2905773T3 (es) | 2022-04-12 |
CA2994110A1 (en) | 2017-04-27 |
WO2017069819A1 (en) | 2017-04-27 |
AU2021215167A1 (en) | 2021-09-02 |
JP2018531051A (ja) | 2018-10-25 |
CA2994110C (en) | 2023-02-21 |
SG11201800734QA (en) | 2018-05-30 |
EP3364925B1 (en) | 2021-12-08 |
AU2016342091B2 (en) | 2021-05-27 |
HK1252431A1 (zh) | 2019-05-24 |
EP3364925A1 (en) | 2018-08-29 |
AU2016342091A1 (en) | 2018-04-26 |
AU2021215167B2 (en) | 2022-07-28 |
EP3364925A4 (en) | 2019-09-18 |
CN108024870B (zh) | 2022-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6832319B2 (ja) | 網膜光線療法用のシステム及び方法 | |
US10709607B2 (en) | System and process for treatment of myopia | |
US10238542B2 (en) | System and process for retina phototherapy | |
US10285859B2 (en) | System for performing retina photostimulation | |
JP6803084B2 (ja) | 網膜光線療法のためのシステムとプロセス | |
JP2018531051A6 (ja) | 網膜光線療法のためのシステムとプロセス | |
JP2022184907A (ja) | 近視の治療のためのシステムおよびプロセス | |
JP2019514454A (ja) | 緑内障に関する神経保護治療のためのシステムおよびプロセス |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190709 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190710 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200424 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200629 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200917 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201104 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201120 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6803084 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |